Dianox’s Post

❗️ Last chance to register for today’s webinar – Spotlight on antibody–drug conjugates in cancer ❗️ Join Fabrice Barlesi and DIERAS Véronique from 17:30–19:00 (CET) as they discuss the mechanism of action of ADCs as well as the key efficacy and safety data from clinical trials in breast and lung cancer. Our expert panel will also explore current challenges and future directions, such as combining ADCs with other agents. Reserve your place now: https://lnkd.in/ebQfYb52 #ADCs #antibodydrugconjugates #oncology #oncologist #breastcancer #lungcancer #meded #medicaleducation

Many cancer treatments fail to deliver targeted results, leaving patients with harsh side effects and limited progress. Antibody-drug conjugates (ADCs) change this by delivering treatment directly to cancer cells, leading to faster, more effective results with less harm. Dive deep into the ways ADCs are revolutionizing cancer care and giving patients the potential for a better quality of life: https://hubs.ly/Q02TNZ1B0 #precisionmedicine #clinicaltrials #oncology

📰 Drug Discovery World featured POLB 001 in the introduction to its Global Cancer Research Guide, which outlined it as an exciting clinical development in addressing cancer immunotherapy-induced CRS, with potential to enable broader use of cancer immunotherapies in an outpatient setting. Click below to read more (starting page 39) https://lnkd.in/gtSZijU9 #POLB #Oncology

TODAY! FREELIVE WEBINAR! #ADCs - how do they work? What data do we have so far? Treatment challenges? Future directions? Chance to hear from this expert panel, ask your questions, and improve patient care. This should be a good one #meded #oncology #medicaleducation #cme #ime

Moderna is exploring the potential of mRNA in immuno-oncology across various cancer types https://lnkd.in/gWTmSiNH #oncodaily #oncology #cancer #mRNAinImmunooncology #CancerTherapies #AACR24 #InnovativeMedicine #ImprovingOutcomes #MedicalTechnology

Non-Small Cell Lung Cancer (NSCLC) continues to be a primary focus area, with leading companies channeling significant resources into its research. Despite a broader decrease in trial initiations, NSCLC remains crucial for cancer research, reflecting ongoing efforts to enhance therapeutic strategies and patient outcomes in oncology. Dive into Citeline's report for an in-depth review of how disease focus areas are evolving in the clinical trial landscape: https://lnkd.in/gGzP7yTK #Oncology #ClinicalTrials #CancerResearch #NSCLC

💉 The Growing Role of Immunotherapy in Cancer Treatment A new ASCO publication highlights the expanding role of immunotherapy in treating cancer, showcasing how these therapies are transforming outcomes for patients. However, the journey from promising research to patient care depends on clinical trials. Clinical trials play a pivotal role in testing and refining treatments like immunotherapy, ensuring they are safe, effective, and available to those who need them most. By participating in these trials, patients and researchers help shape the future of cancer care. Explore the latest findings: https://buff.ly/4giLaQp #CancerResearch #Immunotherapy #ClinicalTrials #Oncology #HealthcareInnovation

#MEDSIRatASCO Yesterday marked the end of #ASCO24, where Dr. Antonio Llombart Cussac, MEDSIR Senior Scientific Lead, shared his insights on the most significant developments from the conference. A key highlight was the discussion around Antibody-Drug Conjugates (ADCs), not only for breast cancer but also for various other tumors. The advancements in #ADCs represent a significant leap in targeted cancer treatment, offering new hope for patients with difficult-to-treat cancers. The discussions at ASCO24 underscored the potential of these therapies to transform the oncology landscape further. Discover our presence at the congress: https://lnkd.in/dRQUKfMd #MedicalResearch #CancerCare #Innovation

📣 In this first-of-its-kind study, we showed that #Immunotherapy could be used to prevent #Cancer. 🔊 We showed that Immunotherapy decreases secondary cancer by almost 70% (P<0.01). ⚡Our study has paved the way for a revolutionary approach: Preventative Immunotherapy, a promising new avenue in the battle against cancer. 🔔 Check out our abstract in the coming #ASCO24. Cleveland Clinic Merck Bristol Myers Squibb AstraZeneca Roche Jame Abraham, M.D. FACP American Society of Clinical Oncology (ASCO) #ASCO #Oncology #ClevelandClinic

🚀 ASCO 2024 In Depth: Dr Nicholas Mai from Memorial Sloan Kettering Cancer Center presents real-world data on sequential antibody-drug conjugate (ADC) treatment for breast cancer. The study reveals that progression-free survival (PFS) is generally shorter for the second ADC, regardless of treatment order. These findings provide valuable insights into optimizing sequential ADC therapy for breast cancer patients. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #ADC #CancerResearch